Literature DB >> 15216475

Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults.

Edward E Walsh1, Ann R Falsey.   

Abstract

Virus-specific nasal immunoglobulin (Ig) A and serum antibody titers in 67 respiratory syncytial virus (RSV)-infected adults were compared with titers in age-matched uninfected control subjects. Control subjects had significantly higher levels of nasal IgA and serum IgG to the RSV F, Ga, and Gb proteins than infected subjects. Serum neutralizing-antibody titers to group A and B RSV strains were also lower in infected subjects, although differences were not as large. Multivariate analysis found that low RSV-specific nasal IgA was an independently significant risk factor for RSV infection.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15216475     DOI： 10.1086/421524

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  79 in total

1.  Effects of aging on the adaptive immune response to respiratory virus infections.

Authors:  Ross B Fulton; Steven M Varga
Journal:  Aging health       Date:  2009-12-01

2.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.

Authors:  F Eun-Hyung Lee; Ann R Falsey; Jessica L Halliley; Iñaki Sanz; Edward E Walsh
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

3.  Genetic analysis and antigenic characterization of human respiratory syncytial virus group A viruses isolated in Germany 1996-2008.

Authors:  Ortwin Adams; Judith Werzmirzowsky; Hartmut Hengel
Journal:  Virus Genes       Date:  2013-06-18       Impact factor: 2.332

4.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

Review 5.  Respiratory Syncytial Virus Infection: An Illness for All Ages.

Authors:  Edward E Walsh
Journal:  Clin Chest Med       Date:  2016-12-27       Impact factor: 2.878

6.  Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations.

Authors:  N C Salisch; A Izquierdo Gil; D N Czapska-Casey; L Vorthoren; J Serroyen; J Tolboom; E Saeland; H Schuitemaker; R C Zahn
Journal:  NPJ Vaccines       Date:  2019-12-20       Impact factor: 7.344

7.  Viral shedding and immune responses to respiratory syncytial virus infection in older adults.

Authors:  Edward E Walsh; Derick R Peterson; Aja E Kalkanoglu; Frances Eun-Hyung Lee; Ann R Falsey
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

8.  A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.

Authors:  Antonios O Aliprantis; Christine A Shaw; Paul Griffin; Nicholas Farinola; Radha A Railkar; Xin Cao; Wen Liu; Jeffrey R Sachs; Christine J Swenson; Heather Lee; Kara S Cox; Daniel S Spellman; Colleen J Winstead; Igor Smolenov; Eseng Lai; Tal Zaks; Amy S Espeseth; Lori Panther
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

Review 9.  Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.

Authors:  Janyra A Espinoza; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

10.  Humoral immunity to human metapneumovirus infection in adults.

Authors:  Ann R Falsey; Patricia A Hennessey; Maria A Formica; Mary M Criddle; Jamie M Biear; Edward E Walsh
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.